A phase 2/3 multicenter, randomized, double blind study of docetaxel (Taxotere) plus DN-101 [calcitriol] or placebo in androgen independent prostate cancer

Trial Profile

A phase 2/3 multicenter, randomized, double blind study of docetaxel (Taxotere) plus DN-101 [calcitriol] or placebo in androgen independent prostate cancer

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Calcitriol; Docetaxel
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms ASCENT
  • Most Recent Events

    • 20 Feb 2007 Results have been published.
    • 20 Feb 2007 Status change
    • 27 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top